Patient-reported outcomes (PROs) in patients with advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ?50% receiving cemiplimab (CEMI) monotherapy vs chemotherapy (CHEMO): EMPOWER-Lung 1 liver metastases subpopulation

Baramidze, A.Gessner, C.Gogishvili, M.Sezer, A.Makharadze, T.Kilickap, S.Gumus, M.2024-05-192024-05-1920231556-08641556-1380https://hdl.handle.net/20.500.12713/5971[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keywords]Patient-reported outcomes (PROs) in patients with advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ?50% receiving cemiplimab (CEMI) monotherapy vs chemotherapy (CHEMO): EMPOWER-Lung 1 liver metastases subpopulationConference Object184S70S71WOS:000995007600050N/A